BCM
EIGR

Bridgeway Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Bridgeway Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,557
Closed -$32.5K – 1438
2023
Q3 		$32.5K Sell
3,557
-3,333
-48% -$67K ﹤0.01% 1328
2023
Q2 		$146K Buy
6,890
+3,333
+94% +$103K ﹤0.01% 1196
2023
Q1 		$95.7K Buy
+3,557
New +$165K ﹤0.01% 1248
2022
Q3 		– Sell
-1,130
Closed -$214K – 1463
2022
Q2 		$214K Sell
1,130
-2,000
-64% -$403K ﹤0.01% 1080
2022
Q1 		$779K Sell
3,130
-1,167
-27% -$184K 0.02% 835
2021
Q4 		$669K Hold
4,297
– – 0.01% 902
2021
Q3 		$861K Hold
4,297
– – 0.02% 868
2021
Q2 		$1.1M Buy
+4,297
New +$1.07M 0.02% 828
2020
Q1 		– Sell
-3,117
Closed -$1.39M – 1374
2019
Q4 		$1.39M Hold
3,117
– – 0.02% 654
2019
Q3 		$958K Hold
3,117
– – 0.01% 735
2019
Q2 		$991K Hold
3,117
– – 0.01% 739
2019
Q1 		$1.31M Hold
3,117
– – 0.02% 665
2018
Q4 		$950K Hold
3,117
– – 0.01% 751
2018
Q3 		$1.12M Hold
3,117
– – 0.01% 836
2018
Q2 		$1.14M Hold
3,117
– – 0.01% 828
2018
Q1 		$921K Buy
3,117
+784
+34% +$232K 0.01% 882
2017
Q4 		$977K Hold
2,333
– – 0.01% 851
2017
Q3 		$770K Hold
2,333
– – 0.01% 942
2017
Q2 		$553K Buy
2,333
+1,333
+133% +$303K 0.01% 1053
2017
Q1 		$344K Sell
1,000
-189
-16% -$65.1K ﹤0.01% 1179
2016
Q4 		$416K Hold
1,189
– – 0.01% 1143
2016
Q3 		$478K Buy
1,189
+659
+124% +$336K 0.01% 1119
2016
Q2 		$315K Buy
+530
New +$322K ﹤0.01% 1210
2015
Q4 		– Sell
-58
Closed -$27K – 1504
2015
Q3 		$27K Sell
58
-416
-88% -$221K ﹤0.01% 1450
2015
Q2 		$269K Buy
474
+350
+282% +$969K 0.01% 1281
2015
Q1 		$1.06M Hold
124
– – 0.02% 767
2014
Q4 		$1.09M Hold
124
– – 0.02% 733
2014
Q3 		$585K Buy
+124
New +$655K 0.01% 1001

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgeway Capital Management's EIGR Position: Q4 2023 in Review

Bridgeway Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2023, closing a stake of 3,557 shares — an estimated $32.5K sold.

Bridgeway Capital Management first reported a position in EIGR in Q3 2014 and held it in 28 quarters. The position peaked at $1.39M in Q4 2019. 43 funds tracked by Wall St. Rank hold EIGR as of Q4 2023.

  • Bridgeway Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • Bridgeway Capital Management sold 3,557 Eiger BioPharmaceuticals, Inc. shares in Q4 2023, an estimated $32.5K.
  • Bridgeway Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2014 and held it in 28 quarters.
  • Bridgeway Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $1.39M in Q4 2019.
  • 43 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2023.

Based on Bridgeway Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.